Listen on the go
CORRECT!
Next question
touchNEUROLOGY touchNEUROLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Neurological Oncology

    EUROPEAN PARTNER

    An Introduction to Neurological Oncology

    Neurological oncology is a rapidly evolving field, encompassing diagnosis and management of primary and metastatic tumours of the CNS, and complications of systemic cancers or cancer treatment. Neuroimaging advances have allowed accurate screening for intracranial disease at initial cancer diagnosis, precise targeting of intracranial lesions during treatment, and differentiation of treatment effects from disease progression by incorporating functional imaging. Our ability to achieve total resection of gliomas has improved significantly. Other advances include tumour-treating fields; hippocampal-sparing whole-brain radiotherapy (WBRT); WBRT with memantine; parotid-sparing WBRT; use of artificial intelligence with stereotactic radiotherapy; and systemically delivered immunotherapies, including vaccines and immune checkpoint inhibitors.

    Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Neurological Oncology Content

    Alzheimer's Disease and Dementia, Brain Trauma, COVID-19, Epilepsy, Headache Disorders, Neurodegenerative Diseases, Movement Disorders, Multiple Sclerosis, Neuroimmunology, Neurological Oncology, Neurometabolic Disease, Neuromuscular Diseases, Neuropathic Pain, Stroke, Neurosurgery, Paediatric Neurology, Parkinson's Disease, Rare Diseases, Psychiatric Disorders, Sleep Disorders, Central Nervous Disorders, Neuroradiology
    What’s on the horizon for continuing medical education? Insights from touchIME

    In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

    Neurological Oncology, Neurosurgery, Paediatric Neurology, Rare Diseases
    Watch Time: 35 mins
    touchEXPERT FOCUS
    Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life
    CE/CME ACCREDITED Dr AeRang Kim, Dr Rebecca Brown, Dr Kaleb Yohay

    Three experts share insights into the treatment and care of patients with NF1 from childhood to adulthood.

    Learning objectives
    Learning Objectives
    • Formulate strategies to maximize outcomes and quality of life for patients with neurofibromatosis type 1 across all stages of life
    • Apply evidence-based practice to the management of neurofibromatosis type I and the treatment of plexiform neurofibromas in children and adults
    • Plan a coordinated transition from paediatric to adult healthcare for patients with neurofibromatosis type 1
    Alzheimer's Disease and Dementia, Brain Trauma, COVID-19, Epilepsy, Headache Disorders, Neurodegenerative Diseases, Movement Disorders, Multiple Sclerosis, Neuroimmunology, Neurological Oncology, Neurometabolic Disease, Neuromuscular Diseases, Neuropathic Pain, Stroke, Neurosurgery, Paediatric Neurology, Parkinson's Disease, Psychiatric Disorders, Sleep Disorders, Central Nervous Disorders, Neuroradiology
    BrainGPT: Advancing neuroscientific research with AI
    Bradley Love

    In this episode, we’re joined by Bradley Love, Professor of Cognitive and Decision Sciences at UCL, ELLIS fellow, and creator of BrainGPT. We discuss how this large language model is poised to assist researchers in advancing their work.

    Neurological Oncology
    Brain Metastases – Clinical Challenges and Recent Advances
    Riccardo Soffietti

    European Neurological Review. 2019;14(1):20–1 DOI: https://doi.org/10.17925/ENR.2019.14.1.20

    Brain metastases (BM) are the most frequent among intracranial brain tumours and their incidence is rising as therapeutic advances are improving the survival of patients with advanced cancer. The incidence of BM has been calculated as 9–17% based on various studies, although the true incidence is thought to be higher.1 Patients with BM have a […]

    Neurological Oncology
    Soffietti_T2.png
    Riccardo Soffietti, EAN 2018 – Advances in personalised therapies for brain tumours (Part 2)

    Riccardo Soffietti (EAN Programme Committee; Chairman, Department of Neuro-Oncology, University and City of Health and Science Hospital, Turini, Italy) talks to us about the topic of the symposium he participated in entitled: Advances in molecular characterisation and personalised therapies in brain tumours. Part 2 of 2. Questions 1. What are the most promising agents targeting […]

    Neurological Oncology
    Soffietti_T1.png
    Riccardo Soffietti, EAN 2018 – Advances in personalised therapies for brain tumours (Part 1)

    Riccardo Soffietti (EAN Programme Committee; Chairman, Department of Neuro-Oncology, University and City of Health and Science Hospital, Turini, Italy) talks to us about the topic of the symposium he participated in entitled: Advances in molecular characterisation and personalised therapies in brain tumours. Part 1 of 2. Questions 1 What have been the most important recent […]

    Neurological Oncology
    Soffietti_T.png
    EAN 2017 – Riccardo Soffietti Interview – Part 3

    EAN Programme Committee Member, Prof. Riccardo Soffietti, provides his insights on neuro-oncology coverage at this year’s EAN congress. Part 3 of 3. View Part 1 here. View Part 2 here. Speaker disclosures: nothing to disclose in relation to this video interview. Filmed at the 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, June […]

    Neurological Oncology
    Soffietti_T.png
    EAN 2017 – Riccardo Soffietti Interview – Part 2

    EAN Programme Committee Member, Prof. Riccardo Soffietti, talks about unmet needs and what he considers will be the most exciting/promising developments in neuro-oncology over the next 2 years. Part 2 of 3. View Part 1 here. View Part 3 here. Speaker disclosures: nothing to disclose in relation to this video interview. Filmed at the 3rd […]

    Neurological Oncology
    Soffietti_T.png
    EAN 2017 – Riccardo Soffietti Interview – Part 1

    EAN Programme Committee Member, Prof. Riccardo Soffietti, discusses the most significant recent developments in neuro-oncology. Part 1 of 3. View Part 2 here. View Part 3 here. Speaker disclosures: nothing to disclose in relation to this video interview. Filmed at the 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, June 2017.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup